Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review

Approximately 70% of newly diagnosed breast cancers are of the HR+/HER2- subtype. For the treatment of patients with HR+/HER2- metastatic breast cancer, current guidelines recommend the use of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in combination with endocrine therapy. In this...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Emilie Adrian Christiansen, Iben Kümler
Format: Artigo
Sprog:Inglês
Udgivet: Taylor & Francis Group 2024-12-01
Serier:Future Science OA
Fag:
CDK4/6 inhibitor
HR+/HER2-
metastatic breast cancer
overall survival
palbociclib
progression-free survival
Online adgang:https://www.tandfonline.com/doi/10.2144/fsoa-2023-0074
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker